US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Apimeds Pharmaceutical U.S, Inc.

2.11

-0.0650-3.00%

Post-market: 2.10-0.0050-0.24%19:05 EDT

Volume:20.69K

Turnover:44.37K

Market Cap:3.18M

PE:-0.05

High:2.26

Open:2.16

Low:2.09

Close:2.17

52wk High:59.70

52wk Low:2.09

Shares:1.51M

Float Shares:304.73K

Volume Ratio:0.63

T/O Rate:6.79%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-38.5450

EPS(LYR):-0.1759

ROE:-144.99%

ROA:-69.29%

PB:0.39

PE(LYR):-11.97

Loading ...

Overview Company News Filings

Apimeds Pharmaceuticals US - Enters First Amendment to Settlement Agreement on Sept 10, 2026 - SEC Filing

THOMSON REUTERS

Apimeds Pharmaceuticals US - Board to Consist Solely of Four Members During Interim Period - SEC Filing

THOMSON REUTERS

Apimeds Pharmaceuticals US - Board to Expand to Seven Members After Interim Period - SEC Filing

THOMSON REUTERS

Apimeds Pharmaceuticals Adds Co-CEO Sungjoon Chae to Board

Apimeds Pharmaceuticals US Enters Assignment and Transfer Agreement with Freet on August 19

Apimeds Secures Key Apitox Rights via FreeT Agreement

Apimeds Pharmaceuticals US - Freet Assigns All Apitox-Related Rights to Apimeds Pharmaceuticals - SEC Filing

THOMSON REUTERS

Apimeds Pharmaceuticals US - Receives 100% Korean Clinic Rights, 25% U.S. Royalty, 25% Overseas Revenue Participation for Apitox - SEC Filing

THOMSON REUTERS

Apimeds Pharmaceuticals US Gains Apitox Rights in Assignment from South Korea’s FreeT

Apimeds Net Loss Widens to $20.17 Million in Q2 2026; R&D Expenses Rise 47% to $959,742 vs Year-Ago Quarter

Apimeds Pharmaceuticals Names Christopher Kim Chief Scientific Officer

Apimeds Appoints Chief Scientific Officer to Advance APITOX

Apimeds Pharmaceuticals US Inc trading halted, volatility trading pause

Amex Halt Add Info Lst 6.453500

THOMSON REUTERS

Press Release: MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October

Apimeds Pharmaceuticals to Implement Reverse Stock Split July 24

Apimeds Pharmaceuticals Q1 EPS $(2.26) Down From $(0.50) YoY

Benzinga Earnings

Apimeds net loss widens to $35.06 million in Q1 2026; no revenue

Apimeds Pharmaceuticals Delays Quarterly SEC Filing

Apimeds Pharmaceuticals delays quarterly 10-Q filing for March 31, 2026 quarter

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/APUS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"APUS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APUS\",,,,,undefined,":{"symbol":"APUS","market":"US","secType":"STK","nameCN":"Apimeds Pharmaceutical  U.S, Inc.","latestPrice":2.105,"timestamp":1789156800000,"preClose":2.17,"halted":0,"volume":20691,"hourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.105,"latestTime":"19:05 EDT","volume":846,"amount":1777.9794,"timestamp":1789167930883,"change":-0.005,"changeRate":-0.002375,"amplitude":0},"delay":0,"changeRate":-0.029953917050691222,"floatShares":304730,"shares":1509119,"eps":-38.545,"marketStatus":"Market Closed","change":-0.065,"latestTime":"09-11 16:00:00 EDT","open":2.16,"high":2.26,"low":2.09,"amount":44373.616511399996,"amplitude":0.078341,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-38.545,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1746763200000,"exchange":"AMEX","adjPreClose":2.17,"preHourTrading":{"tag":"盘前","latestPrice":2.271,"preClose":2.17,"latestTime":"09:25 EDT","volume":20,"amount":46.8253,"timestamp":1789133145724,"change":0.101,"changeRate":0.046544,"amplitude":0.058249},"postHourTrading":{"tag":"盘后","latestPrice":2.1,"preClose":2.105,"latestTime":"19:05 EDT","volume":846,"amount":1777.9794,"timestamp":1789167930883,"change":-0.005,"changeRate":-0.002375,"amplitude":0},"volumeRatio":0.633923210231696},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APUS\",,,,,undefined,":{"symbol":"APUS","floatShares":304730,"roa":"-69.29%","roe":"-144.99%","lyrEps":-0.175862,"volumeRatio":0.633923210231696,"shares":1509119,"dividePrice":0,"high":2.26,"amplitude":0.078341,"preClose":2.17,"low":2.09,"week52Low":2.09,"pbRate":"0.39","week52High":59.7,"institutionHeld":0,"latestPrice":2.105,"eps":-38.545,"divideRate":0,"volume":20691,"delay":0,"ttmEps":-38.545,"open":2.16,"prevYearClose":16.4,"prevWeekClose":2.42,"prevMonthClose":3.88,"prevQuarterClose":9,"fiveDayClose":2.51,"twentyDayClose":4.7,"sixtyDayClose":11.7},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APUS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-07-24","symbol":"APUS","defaultRemindTime":1784899800000,"type":"split","dateTimestamp":1784865600000,"forFactor":10,"toFactor":1,"ratio":10}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APUS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APUS\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APUS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APUS","date":"2025-12-01","current":-0.054611,"percent":0.642384,"low":-37.866629,"twenty":-14.293061,"median":-12.284712,"eighty":-6.374893,"high":-4.754876,"avg":-11.953693,"sd":7.073766,"marketCap":36470350},"quantilePoints":[{"date":"2025-02-21","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-02-28","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-03-05","current":-34.716764,"twenty":-34.716764,"median":-34.716764,"eighty":-34.716764,"marketCap":57120291},{"date":"2025-05-09","current":-18.309826,"twenty":-34.716764,"median":-34.716764,"eighty":-33.299512,"marketCap":25450475},{"date":"2025-05-16","current":-14.148502,"twenty":-34.716764,"median":-34.008138,"eighty":-15.063993,"marketCap":19666276},{"date":"2025-05-23","current":-14.074662,"twenty":-34.716764,"median":-18.309826,"eighty":-14.306662,"marketCap":21054484},{"date":"2025-05-30","current":-13.387434,"twenty":-34.716764,"median":-15.063993,"eighty":-14.061031,"marketCap":20026450},{"date":"2025-06-06","current":-14.702962,"twenty":-34.716764,"median":-14.800251,"eighty":-13.996937,"marketCap":21994367},{"date":"2025-06-13","current":-14.314495,"twenty":-34.716764,"median":-14.564634,"eighty":-14.061031,"marketCap":21413253},{"date":"2025-06-20","current":-13.774354,"twenty":-33.866413,"median":-14.548195,"eighty":-14.0474,"marketCap":20605249},{"date":"2025-06-27","current":-13.296895,"twenty":-33.299512,"median":-14.356338,"eighty":-13.867215,"marketCap":19891011},{"date":"2025-07-03","current":-13.774354,"twenty":-27.303638,"median":-14.27266,"eighty":-13.727614,"marketCap":20605249},{"date":"2025-07-11","current":-14.006506,"twenty":-17.177946,"median":-14.161274,"eighty":-13.727614,"marketCap":20952529},{"date":"2025-07-18","current":-13.851738,"twenty":-15.354982,"median":-14.154888,"eighty":-13.727614,"marketCap":20721009},{"date":"2025-07-25","current":-16.173259,"twenty":-16.219689,"median":-14.161274,"eighty":-13.727614,"marketCap":24193804},{"date":"2025-08-01","current":-13.464818,"twenty":-16.219689,"median":-14.199966,"eighty":-13.727614,"marketCap":20142210},{"date":"2025-08-08","current":-12.14929,"twenty":-16.049445,"median":-14.148502,"eighty":-13.573156,"marketCap":18174293},{"date":"2025-08-15","current":-12.265366,"twenty":-15.710284,"median":-14.056061,"eighty":-13.418388,"marketCap":18347933},{"date":"2025-08-22","current":-7.697345,"twenty":-15.447843,"median":-14.006506,"eighty":-13.015991,"marketCap":28547481},{"date":"2025-08-29","current":-6.307075,"twenty":-15.306558,"median":-13.929122,"eighty":-12.721932,"marketCap":23391328},{"date":"2025-09-05","current":-6.307075,"twenty":-15.146611,"median":-13.929122,"eighty":-12.474303,"marketCap":23391328},{"date":"2025-09-12","current":-6.578348,"twenty":-15.038217,"median":-13.851738,"eighty":-12.234412,"marketCap":24397407},{"date":"2025-09-19","current":-6.205348,"twenty":-14.9276,"median":-13.774354,"eighty":-7.507455,"marketCap":23014048},{"date":"2025-09-26","current":-6.049367,"twenty":-14.889578,"median":-13.773581,"eighty":-6.849619,"marketCap":22435553},{"date":"2025-10-03","current":-5.832349,"twenty":-14.826776,"median":-13.69697,"eighty":-6.578348,"marketCap":21630690},{"date":"2025-10-10","current":-6.307075,"twenty":-14.675296,"median":-13.542202,"eighty":-6.472551,"marketCap":23391328},{"date":"2025-10-17","current":-6.239257,"twenty":-14.561346,"median":-13.50351,"eighty":-6.415584,"marketCap":23139808},{"date":"2025-10-24","current":-5.879822,"twenty":-14.548195,"median":-13.387434,"eighty":-6.358617,"marketCap":21806754},{"date":"2025-10-31","current":-6.917438,"twenty":-14.538909,"median":-13.039206,"eighty":-6.374893,"marketCap":25655005},{"date":"2025-11-07","current":-8.524725,"twenty":-14.481047,"median":-12.845746,"eighty":-6.381675,"marketCap":31616021},{"date":"2025-11-14","current":-9.460613,"twenty":-14.381444,"median":-12.652286,"eighty":-6.415584,"marketCap":35086992},{"date":"2025-11-21","current":-5.852155,"twenty":-14.312928,"median":-12.458826,"eighty":-6.415584,"marketCap":30182359},{"date":"2025-11-28","current":-7.071353,"twenty":-14.306662,"median":-12.304058,"eighty":-6.374893,"marketCap":36470350},{"date":"2025-12-01","current":-7.071353,"twenty":-14.293061,"median":-12.284712,"eighty":-6.374893,"marketCap":36470350}],"updateTime":1789246506608},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APUS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666522022","title":"Apimeds Pharmaceuticals US - Enters First Amendment to Settlement Agreement on Sept 10, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2666522022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666522022?lang=en_us&edition=fundamental","pubTime":"2026-09-11 21:11","pubTimestamp":1789132313,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN45306Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666220035","title":"Apimeds Pharmaceuticals US - Board to Consist Solely of Four Members During Interim Period - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2666220035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666220035?lang=en_us&edition=fundamental","pubTime":"2026-09-11 21:11","pubTimestamp":1789132313,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN45306Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666006522","title":"Apimeds Pharmaceuticals US - Board to Expand to Seven Members After Interim Period - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2666006522","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666006522?lang=en_us&edition=fundamental","pubTime":"2026-09-11 21:11","pubTimestamp":1789132313,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN45306Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666152207","title":"Apimeds Pharmaceuticals Adds Co-CEO Sungjoon Chae to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2666152207","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666152207?lang=en_us&edition=fundamental","pubTime":"2026-09-11 21:11","pubTimestamp":1789132287,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals adds Co-CEO Sungjoon Chae to boardApimeds Pharmaceuticals US amended a settlement to reset board control ahead of a preferred stock conversion.Interim board set at four directo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL1Kss6C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661226290","title":"Apimeds Pharmaceuticals US Enters Assignment and Transfer Agreement with Freet on August 19","url":"https://stock-news.laohu8.com/highlight/detail?id=2661226290","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661226290?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:31","pubTimestamp":1787347904,"startTime":"0","endTime":"0","summary":"BRIEF-Apimeds Pharmaceuticals US Enters Assignment And Transfer Agreement With Freet On August 19Aug 21 -Apimeds Pharmaceuticals US IncAPUS.A:APIMEDS PHARMACEUTICALS US - ENTERS ASSIGNMENT AND TRANSFER AGREEMENT WITH FREET ON AUG 19, 2026 - SEC FILINGAPIMEDS PHARMACEUTICALS US - FREET ASSIGNS ALL APITOX-RELATED RIGHTS TO APIMEDS PHARMACEUTICALS - SEC FILINGAPIMEDS PHARMACEUTICALS US - RECEIVES 100% KOREAN CLINIC RIGHTS, 25% U.S. ROYALTY, 25% OVERSEAS REVENUE PARTICIPATION FOR APITOX - SEC FILINGAPIMEDS PHARMACEUTICALS US - ASSIGNED RIGHTS ARE FREE AND CLEAR OF PRIOR CLAIMS OR ENCUMBRANCES - SEC FILINGSource text: [ID:n0001213900-26-092680]Further company coverage:APUS.A","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0JA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661907092","title":"Apimeds Secures Key Apitox Rights via FreeT Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2661907092","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661907092?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:27","pubTimestamp":1787347671,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Apimeds Pharmaceuticals US, Inc. ( ($APUS) ). On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-secures-key-apitox-rights-via-freet-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-secures-key-apitox-rights-via-freet-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661909292","title":"Apimeds Pharmaceuticals US - Freet Assigns All Apitox-Related Rights to Apimeds Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2661909292","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661909292?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:13","pubTimestamp":1787346814,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0JA:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290926","title":"Apimeds Pharmaceuticals US - Receives 100% Korean Clinic Rights, 25% U.S. Royalty, 25% Overseas Revenue Participation for Apitox - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290926","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661290926?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:13","pubTimestamp":1787346814,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0JA:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290973","title":"Apimeds Pharmaceuticals US Gains Apitox Rights in Assignment from South Korea’s FreeT","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290973","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661290973?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:13","pubTimestamp":1787346799,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US gains Apitox rights in assignment from South Korea’s FreeTApimeds Pharmaceuticals US entered an Aug. 19, 2026 agreement to acquire Apitox-related rights from South Korea’s F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL6CbTxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659612928","title":"Apimeds Net Loss Widens to $20.17 Million in Q2 2026; R&D Expenses Rise 47% to $959,742 vs Year-Ago Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2659612928","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659612928?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:31","pubTimestamp":1786739518,"startTime":"0","endTime":"0","summary":"Apimeds net loss widens to $20.17 million in Q2 2026; R&D expenses rise 47% to $959,742 vs year-ago quarterApimeds posted a net loss of USD 20.17 million for the quarter ended June 30, 2026, widening ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDLbnCjgW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657216669","title":"Apimeds Pharmaceuticals Names Christopher Kim Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657216669","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657216669?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:26","pubTimestamp":1786055210,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals names Christopher Kim chief scientific officerApimeds Pharmaceuticals US appointed Christopher Kim as chief scientific officer, effective Aug. 5, 2026.Kim will lead scientific,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL7MSD0K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669423","title":"Apimeds Appoints Chief Scientific Officer to Advance APITOX","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669423","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669423?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:16","pubTimestamp":1786054579,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has provided an announcement. On August 5, 2026, Apimeds Pharmaceuticals US, Inc. appointed Dr. Christ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-appoints-chief-scientific-officer-to-advance-apitox?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-appoints-chief-scientific-officer-to-advance-apitox?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655037768","title":"Apimeds Pharmaceuticals US Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2655037768","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655037768?lang=en_us&edition=fundamental","pubTime":"2026-07-30 21:50","pubTimestamp":1785419428,"startTime":"0","endTime":"0","summary":"09:48 EDT Apimeds Pharmaceuticals (APUS) US Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apimeds-pharmaceuticals-us-inc-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apimeds-pharmaceuticals-us-inc-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APUS","JULD","QQQP","BK4139","RSEE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655280391","title":"Amex Halt Add Info Lst 6.453500","url":"https://stock-news.laohu8.com/highlight/detail?id=2655280391","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655280391?lang=en_us&edition=fundamental","pubTime":"2026-07-30 21:48","pubTimestamp":1785419330,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nAQN2MCF6T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654047040","title":"Press Release: MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World's First Fully Insured Blockchain, Launching in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2654047040","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654047040?lang=en_us&edition=fundamental","pubTime":"2026-07-28 20:30","pubTimestamp":1785241800,"startTime":"0","endTime":"0","summary":"seconds, about as fast as tapping a bank card, and every transaction is. -- The wallets people already use. Anyone with MetaMask or another popular. crypto wallet can use MindChain today, with nothing new to download or. learn. Developers keep their existing tools too, so apps can launch on. -- A custom chain for every industry. A business can launch its own. dedicated blockchain on top of MindChain, with its own rules, fees, and. speed settings, the way a company might run its own private network. Each. one still gets the full protection of MindChain and Ethereum.own records. Even if bad actors try to write a false transaction, one. honest participant is enough to catch and reject it. False records cannot","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDLC","09179","BITQ","ETHD","STCE","ARKY","ETHE","ETHU","EVM","ETH.USD.HKCC","EZET","SETH","BKCH","EETH","TETH","09009","BETH","APUS","HECO","03179","BITU","BITW","03046","ETU","HODL","ETH","YETH","METHmain","BETE","ETHI","CETH","ETHT","ETHW","FETH","BTF","CRPT","09046","AETH","ETQ","BEGS","03009","ETTY","ETCO","ETH.USD.CC","LFGY","BLOK","QETH","ETHA","BITX","ETHV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651425041","title":"Apimeds Pharmaceuticals to Implement Reverse Stock Split July 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2651425041","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651425041?lang=en_us&edition=fundamental","pubTime":"2026-07-14 05:02","pubTimestamp":1783976554,"startTime":"0","endTime":"0","summary":"An update from Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) is now available. On December 1, 2025, Apimeds Pharmaceuticals US, Inc. obtained majori...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-to-implement-reverse-stock-split-july-24?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-to-implement-reverse-stock-split-july-24?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638352325","title":"Apimeds Pharmaceuticals Q1 EPS $(2.26) Down From $(0.50) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2638352325","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638352325?lang=en_us&edition=fundamental","pubTime":"2026-05-27 05:32","pubTimestamp":1779831143,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals (AMEX:APUS) reported quarterly losses of $(2.26) per share. This is a 352 percent decrease over losses of $(0.50) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52796462/apimeds-pharmaceuticals-q1-eps-2-26-down-from-0-50-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Apimeds Pharmaceuticals Q1 EPS $(2.26) Down From $(0.50) YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638540674","title":"Apimeds net loss widens to $35.06 million in Q1 2026; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2638540674","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638540674?lang=en_us&edition=fundamental","pubTime":"2026-05-27 04:08","pubTimestamp":1779826101,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US posted a net loss of $35.06 million for the quarter ended March 31, 2026, widening from $402,397 a year earlier.Total operating expenses climbed to $12.19 million from $364,368, led by general and administrative costs of $11.28 million.Other expense deepened to $22.87 million from $38,029, driven by $22.08 million of unrealized losses on digital asset holdings.Net cash used in operating activities rose to $2.07 million from $20,313; revenue was unchanged at no revenue.Liquidity included $10.9 million drawn from a $120.9 million PIPE, with $8 million recorded as restricted cash.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDLw1MJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635568056","title":"Apimeds Pharmaceuticals Delays Quarterly SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635568056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635568056?lang=en_us&edition=fundamental","pubTime":"2026-05-16 07:34","pubTimestamp":1778888071,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US, Inc. ( ($APUS) ) has released a notification of late filing. Apimeds Pharmaceuticals US, Inc. has filed a Form 12b-25, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-delays-quarterly-sec-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/apimeds-pharmaceuticals-delays-quarterly-sec-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635371480","title":"Apimeds Pharmaceuticals delays quarterly 10-Q filing for March 31, 2026 quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2635371480","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635371480?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:10","pubTimestamp":1778875800,"startTime":"0","endTime":"0","summary":"Apimeds Pharmaceuticals US filed Form 12b-25 to delay its quarterly report on Form 10-Q for quarter ended March 31, 2026.Filing missed prescribed due date as company finalizes financial statements, citing unreasonable effort or expense to meet deadline.Form 10-Q expected within 5-calendar-day extension period under SEC Rule 12b-25.Notice flagged no anticipated significant change in results of operations versus corresponding prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5x4CYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":57,"code":"91000000","status":"200"}]}}